Human gliomas are the most common and deadly type of primary intracranial tumors and account for approximately 80% of all primary CNS malignancies. Gliomas are histopathologically classified into four tumor grades (I–IV) according to the World Health Organization (WHO). WHO grade IV or glioblastoma multiforme (GBM) confers the worst prognosis, with a median survival time of merely 12 to 15 months following primary diagnosis.
With advancement of gene technology, molecular signatures have become prominent in the classification of gliomas in recent years. Whole-genome analysis of patient cases through The Cancer Genome Atlas (TCGA), revealed a molecular classification scheme for GBM which includes four molecular subtypes: proneural, neural, classical, and mesenchymal. Among these four subtypes, the mesenchymal subtype was distinguished from the others as being particularly aggressive. Thus, there is an urgent need for the exploration of novel biomarkers and therapeutic targets for brain tumor, especially GBM.
The special issue “Molecular Target in CNS malignancies” aims to highlight the significant findings and advances in our understanding of the role of the novel molecular targets, diagnostic biomarkers as well as novel prognostic indicators in CNS malignancies, especially GBM.
The special issue “Molecular Target in CNS malignancies” will provide an important forum for exciting findings in Neuro-oncology-related research, presenting an unparalleled opportunity to communicate information to specialists and the public, opening new avenues for the understanding, prevention, diagnosis and treatment of brain tumor patients.
Aims and Scope:
- Molecular targeted therapies
- Prognostic indicators of CNS malignancies
- Clinical trials and pre-clinical studies of neuro-oncology
- Cancer antigens and immune checkpoint
- Molecular mechanisms of drug resistance in CNS malignancies
- RNA-seq and proteomics study of CNS malignancies